Is Metrohm AG profitable?

No public profit figures are disclosed since Metrohm is 100% owned by the non-profit Metrohm Foundation and has no public stock. The last disclosed revenue figure is over CHF 400 million as of 2021, and the company remains debt-free and self-financed with no external loans.

Metrohm AG has been 100% owned since 1982 by the non-profit Metrohm Foundation, set up by founder Bertold Suhner with Hans Winzeler and Lorenz Kuhn specifically to keep the company independent of outside shareholders and lenders.

Could AI replace Metrohm's analytical instruments?

Unlikely soon: as of mid-2026 AI only touches Metrohm's chemometrics (Vision software) and OMNIS reporting/cloud layer (AWS/Azure hosting added June 2025). Physical instrument manufacturing and 21 CFR Part 11 regulatory-validated workflows remain outside any shipped AI product.

Is Metrohm laying off employees?

No evidence of layoffs. Revelio Labs style third-party estimates aside, Wikipedia reports about 3,200 employees worldwide as of 2024 with 700 at the Herisau HQ, alongside continued new-subsidiary openings in Korea, Portugal, and Ghana through 2025.

Who is Metrohm's biggest competitor?

Thermo Fisher Scientific (Dionex ion chromatography line) and Mettler-Toledo (titration) are the closest head-to-head rivals, alongside Agilent, Shimadzu, and diversified giant Danaher, all competing in the same titration, IC, and spectroscopy categories as of 2026.

Is Metrohm a public company or does it have a stock ticker?

Metrohm AG is privately held with no public stock or ticker; it has been fully owned by the non-profit Metrohm Foundation since 1982 and has never raised external or venture funding.

Biotech tools companies · Switzerland

Metrohm AG

metrohm.com ↗

Swiss maker of titration and ion chromatography instruments for regulated labs.

Hard to displace

Assessed 24 July 2026 · Evidence as of 24 July 2026

Strong structural protection; the business model survives ai pressure.

On the recordSince 24 July 2026 · Checkable from 2027 · Every call on the record Checkpoint: EU Cyber Resilience Act compliance deadlines hit connected lab software, including OMNIS

The call

Metrohm keeps growing headcount and facilities on its own cash while big rivals compete but haven't dislodged its regulated-lab customers.

Metrohm is a Swiss company, owned by a nonprofit foundation, that sells machines to check the purity and quality of medicines and chemicals. It is hard to replace because hospitals and drug makers have already installed Metrohm equipment, the machines work reliably, and switching to a rival like Thermo Fisher or Mettler-Toledo costs time and money. The one thing that could change this is if those bigger competitors build smarter software that works with their lab machines, or if AI tools make the testing process so different that old machines become less useful.

Why

AI pressure: None apparent. No AI lab product yet reads regulated titration/IC data well enough to replace Metrohm's instruments or software. Could AI do the core job? Unlikely.

Bigger players: Thermo Fisher Scientific and Danaher (Mettler-Toledo, Dionex). Both sell competing titration and IC lines today, but neither has shown it can pull Metrohm's installed customers away. Could a giant copy it? Yes, easily.

What protects it. Regulated labs stay on Metrohm once validated: 21 CFR Part 11 records, spectral libraries, and a service network in 80+ countries make switching costly.

What would change this call

Thermo Fisher or Danaher ships a bundled cloud+AI lab-data platform for titration/IC by 2027. Would show a giant is directly targeting Metrohm's OMNIS software differentiation.
Metrohm reports flat or declining headcount or facility consolidation in an annual update. Would signal the current expansion trend (subsidiaries, campus growth) has reversed.
New Ghana, Portugal, or Korea subsidiaries report weak uptake or closure within a year of opening. Would indicate Metrohm's distribution expansion is not gaining traction.

Key numbers

Founded April 1, 1943 in Herisau, Switzerland (1943)
100% owned by non-profit Metrohm Foundation (1982)
Swiss parent headcount up 14% from 2023 to 2025 (2025-12-31)

Named risks

Giant rival ships bundled cloud plus AI regulated-lab platform eroding OMNIS differentiation. Severity: medium
EU Cyber Resilience Act and GMP compliance costs could squeeze margins for a focused independent. Severity: medium
Swiss CHF cost base pressure relative to competitors manufacturing in lower-cost regions. Severity: medium
No public financials since 2021 makes current profitability and margin trends unverifiable. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Thermo Fisher Scientific	contesting	Dionex IC line competes head-on with Metrohm IC systems, no reported displacement wins as of 2026
Mettler-Toledo	contesting	Direct titration rival with far larger revenue scale (~$4.03B) but no reported Metrohm account losses
Danaher	contesting	Diversified conglomerate flagged as potential AI-native lab platform threat, none shipped as of 2026
Agilent Technologies	contesting	Named peer in chromatography/spectroscopy instrumentation, no head-to-head displacement reported
Shimadzu	contesting	Named peer competitor in analytical instrumentation category as of 2026

Questions people ask

Is Metrohm AG profitable?: No public profit figures are disclosed since Metrohm is 100% owned by the non-profit Metrohm Foundation and has no public stock. The last disclosed revenue figure is over CHF 400 million as of 2021, and the company remains debt-free and self-financed with no external loans.
Who owns Metrohm?: Metrohm AG has been 100% owned since 1982 by the non-profit Metrohm Foundation, set up by founder Bertold Suhner with Hans Winzeler and Lorenz Kuhn specifically to keep the company independent of outside shareholders and lenders.
Could AI replace Metrohm's analytical instruments?: Unlikely soon: as of mid-2026 AI only touches Metrohm's chemometrics (Vision software) and OMNIS reporting/cloud layer (AWS/Azure hosting added June 2025). Physical instrument manufacturing and 21 CFR Part 11 regulatory-validated workflows remain outside any shipped AI product.
Is Metrohm laying off employees?: No evidence of layoffs. Revelio Labs style third-party estimates aside, Wikipedia reports about 3,200 employees worldwide as of 2024 with 700 at the Herisau HQ, alongside continued new-subsidiary openings in Korea, Portugal, and Ghana through 2025.
Who is Metrohm's biggest competitor?: Thermo Fisher Scientific (Dionex ion chromatography line) and Mettler-Toledo (titration) are the closest head-to-head rivals, alongside Agilent, Shimadzu, and diversified giant Danaher, all competing in the same titration, IC, and spectroscopy categories as of 2026.
Is Metrohm a public company or does it have a stock ticker?: Metrohm AG is privately held with no public stock or ticker; it has been fully owned by the non-profit Metrohm Foundation since 1982 and has never raised external or venture funding.

Timeline

2026-05-29Announced UK distribution partnership with KPM Analytics
2026-03-31Announced i-Raman Plus laboratory Raman platform
2026-03-24Opened new Houston, Texas facility for Metrohm USA
2025-11Launched Optrode M2
2025-10Launched i-Raman NxG
2025-05-27Major OMNIS update added AWS/Azure cloud hosting and LIMS integration
2025-01Opened new subsidiary in Portugal
2024-04Launched OMNIS NIRS near-infrared spectroscopy module
2024Expanded Herisau campus by 20,000 square meters
1982Ownership transferred fully to non-profit Metrohm Foundation
1943-04-01Metrohm founded in Herisau by Bertold Suhner and Willi Studer

Revision history

24 July 2026

First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.

In the same band

Merck KGaA (MilliporeSigma)Intertek Group plc Eurofins Scientific SE